[Cutaneous lupus induced by etanercept in rheumatoid arthritis].
Therapy with anti-TNFalpha in rheumatoid arthritis may induce autoimmune disorders. Induction of autoantibodies is frequently observed, but lupus-like syndrome is rare and few cases only have been reported. We report a 41-year-old female, treated with etanercept for a rheumatoid arthritis, who developed a cutaneous lupus induced without any other organ involvement, associated with high ANA and DNA antibody titres. The skin biopsy and the histological analysis with immunofluorescence confirmed the diagnosis. The anti-TNFalpha treatment was stopped. Corticosteroids were increased and hydroxychloroquine administered because skin lesions persist after three months.
Abourazzak
F E
FE
Service de rhumatologie, hôpital El-Ayachi, CHU de Rabat-Salé, 10000 Rabat-Salé, Maroc. abourazakf@yahoo.fr
Guggenbuhl
P
P
Perdriger
A
A
Meadeb
J
J
Gando-Cocley
N
N
Chevrant-Breton
J
J
Hajjaj-Hassouni
N
N
Chalès
G
G
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept